3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Breast Neoplasms
2
Thrombocytosis
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Breast Cancer With Intracranial Metastases
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hormone-Resistant Prostate Cancer
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Diarrhea
1
Brain Neoplasms
1
Blast Crisis
1
Anemia
1
Interventions
Dexamethasone
29
Cyclophosphamide
21
Rituximab
17
Cytarabine
16
Bortezomib
13
Gemcitabine
12
fludarabine
11
Methotrexate
11
Lenalidomide
10
Filgrastim
10
Vincristine
9
Etoposide
9
pomalidomide
8
pembrolizumab
8
Paclitaxel
8
Azacitidine
8
venetoclax
7
carfilzomib
7
Doxorubicin
7
Docetaxel
7
Cyclosporine
7
Calcium Dobesilate
7
Antilymphocyte Serum
7
fludarabine phosphate
6
Topotecan
6
Temozolomide
6
Radiotherapy
6
Peripheral Blood Stem Cell Transplantation
6
Mitoxantrone
6
daratumumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Recurrence
×
XRP6258
×
Clear all
NCT02166658
2018-01-23
CaBaMet
AIO-Studien-gGmbH
Phase 2
Terminated
8 enrolled